Corcept Therapeutics Incorporated
CORT
Rang in aandelen
#1760
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Aandeelprijs
$112.58
Marktkapitalisatie
$12.17B
Verandering (1 dag)
0.43%
Verandering (1 jaar)
43.23%
Land
US
Handel Corcept Therapeutics Incorporated (CORT)
Categorie
Healthcare
P/B-ratio voor Corcept Therapeutics Incorporated (CORT)
P/B-ratio op October 2026 TTM: 17.35
Volgens de meest recente financiële rapporten en aandelenkoers van Corcept Therapeutics Incorporated is de huidige P/B-ratio (TTM) 17.35. Eind 2023 had het bedrijf een P/B-ratio van 6.64.
P/B-ratiohistoriek voor Corcept Therapeutics Incorporated van 2001 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 17.35 | 126.85% |
| 2024 | 7.65 | 15.31% |
| 2023 | 6.64 | 53.60% |
| 2022 | 4.32 | -29.07% |
| 2021 | 6.09 | 5.62% |
| 2020 | 5.77 | 54.77% |
| 2019 | 3.73 | -38.76% |
| 2018 | 6.09 | -43.31% |
| 2017 | 10.74 | -44.66% |
| 2016 | 19.40 | -32.53% |
| 2015 | 28.75 | -132.16% |
| 2014 | -89.41 | -686.49% |
| 2013 | 15.25 | 608.08% |
| 2012 | 2.15 | -73.70% |
| 2011 | 8.19 | -34.07% |
| 2010 | 12.42 | 88.15% |
| 2009 | 6.60 | 134.13% |
| 2008 | 2.82 | -60.76% |
| 2007 | 7.18 | 62.61% |
| 2006 | 4.42 | 42.36% |
| 2005 | 3.10 | 23.71% |
| 2004 | 2.51 | -75.71% |
| 2003 | 10.33 | -375.72% |
| 2002 | -3.75 | -227.48% |
| 2001 | 2.94 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 3.8424 | -77.86% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.4753 | -85.74% |
HK
|
